37 results
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
8:00am
efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScan’s business or operations; and other factors
8-K
EX-99.1
b8kf8 3dtwe3
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
8-K
EX-99.1
imsx8na i3q5z1dv
10 Aug 23
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:15am
8-K
EX-99.1
716hdag
29 Jun 23
TScan Therapeutics Announces Transition of Chief Financial Officer
8:30am
DEFA14A
vljan13eyi1ldpap57
2 Jun 23
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
2n1zn452 z02wn
9 May 23
Amgen and Tscan Therapeutics Announce Collaboration to Identify Novel Targets In Crohn’s Disease
9:15am
8-K
EX-99.1
ijrkx
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
EX-10.1
st473ddkwdg4
12 Sep 22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
7:51am
8-K
EX-99.1
n0ihc mj1
12 Sep 22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
7:51am
8-K
EX-99.1
g1llwt d16c
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
8-K
EX-99.1
fwgk6w w83c
31 May 22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
7:07am